MedPath

Evaluation of the effects of melatonin supplementation in patients with type 2 diabetes

Phase 3
Not yet recruiting
Conditions
E16.1Other
Diabetic nephropathy.
Chapter IV Endocrine, nutritional and metabolic diseases(E00-E90)
Registration Number
IRCT20230212057393N3
Lead Sponsor
Mazandaran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
38
Inclusion Criteria

All patients with type 2 diabetes whose nephropathy was diagnosed through ACR test (>30 mg/gr) during a three-month period

Exclusion Criteria

Patients with heart failure
Pregnant mothers
Lactating mothers
Sensitivity to melatonin and its analogues and simultaneous use of interfering drugs such as fluvoxamine,...
Patients with urinary tract infections and uncontrolled blood pressure

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.